Palomba Stefano, Morelli Michele, Di Carlo Costantino, Noia Roberto, Pellicano Massimiliano, Zullo Fulvio
Chair of Obstetrics and Gynecology, University of Catanzaro, Catanzaro, Italy.
Fertil Steril. 2002 Jul;78(1):63-8. doi: 10.1016/s0015-0282(02)03149-7.
To study the bone metabolism in postmenopausal women who have been treated with gonadotropin-releasing hormone agonist (GnRH-a) and tibolone.
Prospective, open, controlled clinical trial.
Department of Gynecology and Obstetrics, University of Catanzaro, Catanzaro, Italy.
PATIENT(S): One hundred twenty perimenopausal women with symptomatic uterine leiomyomas (groups A and B), and 40 healthy control women who underwent a normal spontaneous menopause (group C).
INTERVENTION(S): Treatment for 12 months with leuprolide acetate plus tibolone (group A) or hysterectomy with bilateral oophorectomy (group B).
MAIN OUTCOME MEASURE(S): Lumbar spine bone mineral density (BMD) and bone turnover markers at entry into the study, after medical treatment (only group A), and 12 months after discontinuation medical treatment (group A) or after surgery (group B). The same parameters were noted in healthy women before and 12 months after menopause (retrospective control group, group C).
RESULT(S): At the women's entry into the study, no significant difference in BMD and bone turnover markers was detected between groups A and B. In group A, no significant variation in BMD or bone turnover markers was observed 12 months after medical treatment in comparison with baseline. At 12 months after discontinuation of treatment (in women who had achieved menopause) and after surgery, we observed a statistically significant decrease in BMD and in bone turnover markers in both groups in comparison with baseline. At 12 months after they became menopausal, we also observed a statistically significant reduction in BMD and in bone turnover markers in control group C. At the same 12-month follow-up visit, a statistically significant difference in BMD and in bone turnover markers was detected when comparing groups A and B with group C.
CONCLUSION(S): Women previously treated with GnRH-a and tibolone similar to women who are menopausal as a result of surgery, have higher bone loss after menopause.
研究接受促性腺激素释放激素激动剂(GnRH-a)和替勃龙治疗的绝经后女性的骨代谢情况。
前瞻性、开放性、对照临床试验。
意大利卡坦扎罗大学妇产科。
120名有症状子宫平滑肌瘤的围绝经期女性(A组和B组),以及40名自然绝经正常的健康对照女性(C组)。
醋酸亮丙瑞林加替勃龙治疗12个月(A组)或子宫切除加双侧卵巢切除(B组)。
研究开始时、药物治疗后(仅A组)以及停药12个月后(A组)或手术后12个月(B组)的腰椎骨密度(BMD)和骨转换标志物。在健康女性绝经前和绝经后12个月记录相同参数(回顾性对照组,C组)。
在女性进入研究时,A组和B组之间的BMD和骨转换标志物未检测到显著差异。在A组中,药物治疗12个月后与基线相比,BMD或骨转换标志物未观察到显著变化。在停药12个月后(已绝经女性)和手术后,与基线相比,两组的BMD和骨转换标志物均出现统计学显著下降。在绝经后12个月时,我们还观察到C组的BMD和骨转换标志物出现统计学显著降低。在相同的12个月随访中,比较A组和B组与C组时,BMD和骨转换标志物存在统计学显著差异。
先前接受GnRH-a和替勃龙治疗的女性与因手术绝经的女性相似,绝经后骨质流失更高。